Vanderbilt University Medical Center | Strategic Alliance Partners

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

Nearly 60% of patients taking vibegron remained on treatment at 1 year.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

The CR rate was 71% in patients with BCG-unresponsive NMIBC with CIS with or without papillary disease.

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

“I always encourage urologists and physicians in general to keep up with the organizations that they're a part of, like the AUA, that often advocate on your behalf," says Ruchika Talwar, MD.

“A key point is the supply chain is very fragile, and there's not really a good financial incentive to make these drugs," says Ruchika Talwar, MD.

“Having a broader understanding of why someone might be experiencing the disease process or symptoms that they're coming in with is really meaningful and helpful, both to patients and to physicians,” says William Furuyama, MD.

"I think targeting things that make communities more vulnerable would be reasonable things to target to try and affect disease practices," says William Furuyama, MD.

"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.

"It was interesting to think about the relationship between a disease process and a person's environment, and measure that and establish that relationship in a quantitative way," says William Furuyama, MD.

WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.

"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says Brendan T. Frainey, MD.

"The goal for this study was to understand, over the lifetime in individuals with spina bifida, what bacteria are present in their urine normally, what bacteria are present when they have a UTI, and what are some important clinical differences we can tease out to help understand which patients should really be treated," says Brendan T. Frainey, MD.

"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E. Corona, MD.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

"Access to clean water and having reliable sewage systems is a huge public health issue," says Elisabeth M. Sebesta, MD.

Data showed that Hispanic patients were consistently underrepresented in clinical trials, while Black participants tended to be overrepresented.

"I think that coping is a key way that we can help intervene here," says Elisabeth M. Sebesta, MD.

"One day, we're going to have to move away from fee for service, so we'd be wise to try to navigate those waters ahead of time, so we're not left dealing with the aftermath when someone else has implemented it for us," says Ruchika Talwar, MD.

"In terms of the psychosocial aspect of things, people with toilet insecurity are more likely to experience greater stress and anxiety, report poorer social support, have a poor overall perception of their health, even after controlling for some confounders," says Elisabeth M. Sebesta, MD.

"17% answered positively to 1 of our questions indicating they might be at risk for some sort of home toilet or sanitation insecurity, or at least they experienced some sort of worry or stress about having access consistently to a working toilet in their home," says Elisabeth M. Sebesta, MD.

"In [bladder cancer], many women's diagnosis is delayed because their hematuria or microscopic hematuria is blamed on urinary tract infections rather than cancer," says Amy Luckenbaugh, MD.

Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the Revi System, specifically touching on how the device may be used as a potential earlier line of therapy for patients with OAB.

"It is important as a field that we recognize the potential emotional impact of surgical adverse events," writes Amy N. Luckenbaugh, MD.

"I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better," says Jeffrey Tosoian, MD, MPH.

"At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable as possible," says Ruchika Talwar, MD.

The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

"There's...this concept of the virtualist; truly, the virtual urologist who has a potentially full-time telehealth practice but geared toward really delivering care, and these positions exist," says Kara L. Watts, MD.

Data showed that treatment with radical prostatectomy was associated with worse urinary incontinence but not worse sexual function compared with other treatment options, regardless of cancer risk.